Vivos Therapeutics Reports Revenue Growth Amid Widening Annual Losses

Vivos Therapeutics Inc (VVOS) has released its full-year financial results, highlighting a period of top-line growth that was offset by deepening operational losses. The results suggest a company attempting to scale its market presence while facing rising costs. For the fiscal year, the company reported total revenue of $17.44 million, representing a 16.0% increase over the $15.03 million recorded in the prior year. This growth indicates a steady increase in the adoption or sales of the company's therapeutic offerings. Despite the revenue gains, the bottom line deteriorated significantly. Vivos reported a net loss of $21.17 million for the period, a sharp increase from the $11.14 million loss reported in the previous year. This widening gap between revenue and expenditure underscores the financial pressure on the firm's operational efficiency. On a per-share basis, the company reported earnings per share (EPS) of -$2.07. While this is a marginal improvement over the -$2.22 EPS from the prior year, the overall increase in total net loss remains the primary focal point for analysts. Market participants are likely to view these results as a sign of continued volatility for the small-cap healthcare provider. The company's path to profitability remains unclear as expenses continue to outpace revenue growth.